Login to Your Account



Abbvie: Top-line phase III endometriosis data good; Neurocrine shares jump

By Randy Osborne
Staff Writer

Thursday, January 8, 2015

Investors will have to wait until later this year for detailed data on such matters as bone mineral density – as well as phase IIb results from a separate, earlier-stage study in uterine fibroids – but the six-month top-line results from the first of two phase III trials with oral elagolix for endometriosis put a spark in shares of Neurocrine Biosciences Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription